Sanofi a beneficiary of Alnylam's data on heart drug Amvuttra

RomanBabakin Sanofi ( NASDAQ: SNY ) is up ~3% in Monday afternoon trading as it stands to benefit from positive data released earlier in the day on Alnylam Pharmaceuticals' ( ALNY ) Amvuttra (vutrisiran). The data was on the drug in treating ATTR amyloidosis with cardiomyopathy. The therapy was already approved for polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

Sanofi ( SNY ) receives tiered royalties of 15%-30% on Amvuttra sales, according to Citi analyst Peter Vernault, who also called the drug an "underappreciated multi-billion dollar royalty stream." More on Sanofi Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi: A Leader In Life-Saving Vaccines And Treatments Sanofi Q1: Wait And See For Now (Downgrade) Innate falls on updated phase 1/2 data on blood cancer asset teamed with Sanofi CDC 'preparing for the possibility' bird flu could spread more easily.